![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genflow Biosciences Plc | LSE:GENF | London | Ordinary Share | GB00BP2C3V08 | ORD GBP0.0003 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 7.32% | 2.20 | 2.10 | 2.30 | 2.20 | 2.05 | 2.05 | 729,631 | 13:13:56 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 169k | -1.63M | -0.0047 | -4.68 | 7.17M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/5/2024 07:17 | Would be great to see another rise today. Big positions still being taking. Free float is dry. Rerate happening | ![]() northeast14 | |
16/5/2024 21:25 | Genflow's collaborative partner for the delivery of SIRT6 and key to advancing the GMP manufacturing of its lead drug candidate. Gla :-) 18/4/24 "EXO Biologics recently created ExoXpert as an exosome CDMO to meet the demand for specialized GMP grade exosome manufacturing services internationally. As a therapeutic exosome developer, this was something EXO Biologics needed, but we also realized the international market needed this as well," said Hugues Wallemacq, CEO, ExoXpert and EXO Biologics. "ExoXpert has started working with a significant number of international cell and gene therapy developers that need a combination of exosome manufacturing and knowledge to develop new products for the benefit of patients. Partnering with Neucore will enable ExoXpert to further extend ExoXpert’s expertise in loading exosomes to Neucore’s FiXE platform.” | ![]() moneymunch | |
16/5/2024 21:16 | 7/5/24 Outlook for 2024 Our key objectives for 2024 are: · Continuing to identify suitable grant funding to support the Group's project pipeline. · Undertake key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of our lead drug candidate, GF-1002, and its potential benefits for MASH patients. · Select site and QMS framework for clinical readiness, expected by the end of 2025 for the MASH program. · Commence preliminary discussions with the European Medicines Agency (EMA) on Mechanism of Action (MoA) data for Orphan Drug Application (ODA) for our second compound GF-3001, targeting Werner Syndrome. · Select Contract Development and Manufacturing Organization (CDMO) for advancing the GMP manufacturing of the MASH clinical lot of lead drug candidate, GF-1002. · Develop and implement project management, budgeting and governance for collaborative partners, in line with clinical and pre-clinal activities that will enable IND applications. · Move key patent applications under the Patent Cooperation Treaty (PCT) to the national phase, while further expanding our development pipeline with new products and new indications. | ![]() moneymunch | |
16/5/2024 19:24 | Must be news coming, certainly lots of big news that could drop at any time 👍🙏 | ![]() steg | |
16/5/2024 18:10 | Great day! | ![]() northeast14 | |
16/5/2024 16:48 | We could open above 2.4p at this rate. Gla holders...Excitement building;-))) | ![]() moneymunch | |
16/5/2024 16:44 | Encouraging action late-on, but I won't be getting excited until we close above 2.4p... GLA | ![]() cyberbub | |
16/5/2024 15:54 | Got a feeling the free float has been mopped UP!!! :-) | ![]() moneymunch | |
16/5/2024 15:46 | Good news could drop at anytime to add significant value, but "The first payment of €777,000 from the 2.89m Euros grant is due to be received imminently" as stated in last week's results and confirmed in today's LinkedIn post...and so confirmation should be very well received. Gla...On and UP!!!:-) | ![]() moneymunch | |
16/5/2024 15:37 | Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 1,606 followers 3h The #biotech space has continued to out perform expectations. As the industry is teetering on another market rally, many companies have had exciting developments. Regeneron, for one, has announced it successfully restored the hearing of two children experiencing otoferlin hearing loss. Additionally, Genflow Biosciences (LON:GENF) (OTCQB:GENFF) has secured several significant grants, some of whose payment is expected imminently. These will help advance its #sarcopenia & #mRNA delivery research. Learn about Genflow's exciting investment proposition: #pharma #aging #GENF | ![]() moneymunch | |
15/5/2024 22:34 | Ditto Northeast, the free float is getting tighter and tighter and so every chance of a decent move North as more buyers arrive in anticipation of the next UPdate or two. Gl :-) | ![]() moneymunch | |
15/5/2024 20:39 | Money, the endless cheap shares can’t go on for ever. Looking forward to seeing more movement very soon | ![]() northeast14 | |
15/5/2024 09:05 | Momentum building with the majority of shares very tightly held!!! Gla holders...On and UP!!! :-) | ![]() moneymunch | |
14/5/2024 20:38 | Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 1,604 followers 8h The #biotech space is cluttered with many companies claiming to be on the cutting edge, with little to back this up. Genflow Biosciences (LON:GENF) (OTCQB:GENFF), on the other hand, stands out in numerous ways. Differentiating between the true innovators and the rest can be difficult. That's why we've created a new fact sheet summarizing our exciting research that aims to extend both human and canine #healthspan. What sets #GENF apart: ✅ Long life IP, protecting our #SIRT6 cenenarian gene & gene delivery research ✅ Creating #NASH treatment to address untapped market of 35 million people ✅ Lead by experienced team with a background running public companies Learn more about Genflow's exciting investment thesis: | ![]() moneymunch | |
14/5/2024 16:40 | Hopefully the unjustified drop is over with now. Someone was very lucky with some cheap shares. | ![]() northeast14 | |
14/5/2024 15:56 | This has certainly required some patience but it looks as though things are starting to get under way at last. Interest appears to be building. GLA | ![]() felchandbart | |
14/5/2024 15:16 | Bid jumped to 1.95 with no buys showing to justify….yet 👍 | ![]() steg | |
14/5/2024 14:53 | Another 1m plus mopped UP!!! Gla :-) | ![]() moneymunch | |
14/5/2024 11:10 | Lol, a pause in proceedings, £25k plus bought yesterday, £30k Friday, £40k Thursday along with confirmation Mr Swann is accumulating more and he's not the only one who is planning to buy more I reckon. Gl : | ![]() moneymunch | |
14/5/2024 10:32 | GBP200 traded this morning so far... | ![]() cyberbub | |
14/5/2024 07:47 | Anytime soon Northeast, although I'd prefer the share price to be firmly above 2p and more before the next UPdate arrives, which will be more than likely in the coming days as the share accumulation continues. Gl :-) | ![]() moneymunch | |
14/5/2024 07:29 | Was hoping for an update. Hopefully there is one soon | ![]() northeast14 | |
13/5/2024 11:05 | A 1m buy just been filled. Gla :-) | ![]() moneymunch | |
10/5/2024 20:52 | Looks like a 2m plus late reported buy imho...Gla ;-) | ![]() moneymunch | |
10/5/2024 11:59 | Mr Swann is adding more...the smart Money is accumulating. Gla holders On and UP!!! :-) | ![]() moneymunch |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions